


Capsaicin Cream is Back

Available at all mainline and shortline wholesalers from January 2026



Available at all Mainline and Shortline Wholesalers

PIP Code: 033-4243

EAN Code: 5017007607397

The product has undergone a change of ownership from Teva to Ennogen

Axsain® 0.075% w/w Cream Capsaicin

For the symptomatic relief of neuralgia associated with and following Herpes Zoster infections (post-herpetic neuralgia) after open skin lesions have healed and for the symptomatic management of painful diabetic peripheral polyneuropathy.

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

Prescribing Information

Axsain 0.075% w/w Cream
Capsaicin 0.075% w/w Cream

Name(s) and active ingredient: Axsain® (capsaicin) 0.075% w/w
Presentation: Aluminium tubes with epoxyphenolic lining and polypropylene spiked cap containing 45 g Axsain Cream. **Indications:** For the symptomatic relief of neuralgia associated with and following Herpes Zoster infections (post-herpetic neuralgia) after open skin lesions have healed. Also for the symptomatic management of painful diabetic peripheral polyneuropathy. **Dosage and administration:** Adults and Elderly: For topical administration to unbroken skin. Apply a pea sized amount to the affected area 3 or 4 times a day, evenly spaced throughout the day, not more often than every 4 hours. The cream should be gently rubbed in and no residue left on the surface. Hands should be washed after application. Do not apply near the eyes. Patients using Axsain for the treatment of painful diabetic peripheral polyneuropathy should only do so under direct supervision of consultant who has access to specialist resources. Recommended duration of use in the first instance is 8 weeks, after which time the patient's condition should be fully clinically assessed prior to continuation and regularly re-evaluated thereafter. **Children:** Not suitable for use in children. **Contraindications:** Not for use on broken or irritated skin or in patients with known hypersensitivity to capsaicin or any of the excipients. **Precautions and warnings:** Skin irritation has been reported. Wash hands immediately after application. If hands are being treated, wash 30 minutes after application. Avoid inhalation of vapours from the cream as transient irritation of the mucous membranes of the eyes and respiratory tract (including exacerbation of asthma) has been reported. Contact with eyes and mucous membranes should be avoided. Patients should avoid taking a hot bath or shower just before or after applying

Axsain, as it can enhance the burning sensation. Seek medical advice if the condition worsens. Do not use under tight bandages. **Excipients:** Benzyl alcohol may cause mild local irritation. Cetyl alcohol may cause local skin reactions (e.g. contact dermatitis). **Interactions:** No interaction studies have been performed. **Pregnancy and lactation:** Safety during pregnancy or lactation has not been established in either animals or humans. In the small amounts absorbed transdermally, it is unlikely that capsaicin will cause any adverse effects. **Effects on ability to drive and use machines:** Not applicable. **Adverse reactions:** Capsaicin may cause skin irritation or transient burning on application. Burning is more frequent when application schedules of more than 4 times daily are utilised. Burning can be enhanced if too much is used and if it is applied just before or just after a bath or shower. Irritation of the mucous membranes has been reported rarely, resulting in symptoms such as coughing, sneezing and runny eyes. Dyspnoea, wheezing and exacerbation of asthma have also been reported. Consult the Summary of Product Characteristics in relation to other side effects. **Overdose:** Not applicable. **Price:** £14.58 per 45g tube. **Legal category:** POM. **Marketing Authorisation Number:** PL 55612/0090. **Date of last revision of SmPC:** 04/12/2025. **Marketing Authorisation Holder:** Ennogen IP Ltd, Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS. **Job Code:** MED-GB-00466. **Date of flyer preparation:** January 2026. **Prescribing Information can be found here:** www.medicines.org.uk/emc/product/101754/smpc

Adverse events should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Ennogen IP Ltd on Tel: 01322 629 220 or medicalinformation@ennogen.com. For a copy of the SmPC or further medical information, please contact: medicalinformation@ennogen.com

Contact details: Ennogen IP Ltd, Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS.
Email: info@ennogen.com | **Telephone:** +44 (0) 1322 629 220 | **Fax:** +44 (0) 1322 311 897

Ennogen